What the FDA labels say about taking them together
Digoxin and palopegteriparatide
Palopegteriparatide's FDA label of August 12, 2026 names digoxin in its drug interactions section; the digoxin labels PlainMeds reads (3) do not name palopegteriparatide. The palopegteriparatide label: “Monitor for signs and symptoms of orthostatic hypotension. Digoxin Toxicity: Concomitant use with digoxin may predispose to digitalis toxicity if hypercalcemia develops.”
Check it at the source: the digoxin FDA label on DailyMed (effective December 5, 2024, Advanz Pharma (US) Corp.); the palopegteriparatide FDA label on DailyMed (effective August 12, 2026, Ascendis Pharma, Endocrinology, Inc.).
What does the digoxin label say about palopegteriparatide?
Digoxin's label (effective December 5, 2024) and its 2 other brand-application labels do not name palopegteriparatide in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (LANOXIN), Advanz Pharma (US) Corp., effective December 5, 2024 (SPL set d91e3646-4c63-4512-ab22-db39c085c4dc), via openFDA; the full label on DailyMed
What does the palopegteriparatide label say about digoxin?
Palopegteriparatide label, drug interactionsAffected by Serum Calcium Digoxin YORVIPATH increases serum calcium, therefore, concomitant use with digoxin (which has a narrow therapeutic index) may predispose patients to digitalis toxicity if hypercalcemia develops.
Palopegteriparatide label, warnings and precautionsMonitor for signs and symptoms of orthostatic hypotension. ( 5.6 ) Digoxin Toxicity: Concomitant use with digoxin may predispose to digitalis toxicity if hypercalcemia develops.
Source: FDA drug label (Yorvipath), Ascendis Pharma, Endocrinology, Inc., effective August 12, 2026 (SPL set a1fa23fd-c434-443e-9a17-5750578c8602), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Digoxin | Palopegteriparatide | |
|---|---|---|
| Labeled for | Heart failure, Atrial fibrillation | n/a |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $0.133 per tablet 125 mcg tablet | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once